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Abstract
Background: Malignant peripheral nerve sheath tumors are rare tumor entities that originate
from peripheral nerve sheaths and have an unfavorable prognosis. Metastatic spread to the cerebral
parenchyma is absolutely rare. This case report describes the clinical course in a 60-year-old man
whose tumor came to medical attention because of a seizure.
Case presentation: Magnetic resonance imaging demonstrated two intracerebral lesions. The
symptomatic lesion was removed microneurosurgically and histology demonstrated a metastasis
from a malignant peripheral nerve sheath tumor. Postoperatively, whole-brain irradiation was
performed. The primary tumor was identified in the area of the sciatic nerve on the right. Follow-
up 14 months after resection showed that there was no progression of the intracerebral lesions
but an increase in size and number of distant metastases.
Conclusion: There are no generally accepted guidelines for the treatment of malignant peripheral
nerve sheath tumors with cerebral metastases. This case report presents and discusses one
possible therapeutic approach. Due to the poor overall prognosis, the least invasive therapy should
be chosen.
Background
The term "malignant peripheral nerve sheath
tumor"(MPNST) comprises various entities including
malignant schwannoma, neurofibrosarcoma, and neuro-
genic sarcoma. MPNSTs are rare with an incidence of
1:100,000. About half of the tumors occur in patients with
type I neurofibromatosis[1,2]. Interestingly, about 10% of
patients have a history of radiotherapy. Reliable data on
survival is not available due to the rarity of the tumor and
the heterogeneous patient population. One study reports
a 5-year survival rate of 64% [3]as compared with 72–
78% for sarcomas[4]. The prognosis appears to depend on
the tumor size (more unfavorable for tumors >5 cm), the
histological grade and the resection margin in patients
operated on[2]. There are two different grading classifica-
tions: One depends on the World Health Organisation
(WHO) classification for soft-tissue tumors with a grading
scale from I-III, the other one on the WHO classification
for tumors of the nervous system with a grading scale
IIIandIV[5,6]. The cell type from which MPNSTs are
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derived has not been yet identified. According to the
WHO definition, MPNSTs are tumors that arise from a
peripheral nerve or histologically show nerve sheath dif-
ferentiation[2]. MPNST is a highly aggressive tumor with
a high rate of local recurrence and pulmonary and visceral
metastatic spread. Brain metastases are extremely rare and
only eleven cases have been published since 1963. We
report the case of a 60-year-old man presenting with the
initial symptom of a focal seizure and in whom magnetic




A 60-year-old man with mental retardation of unclear ori-
gin who was otherwise healthy suffered a focal seizure
with speech disturbance. Two intracerebral lesions were
identified by magnetic resonance imaging (MRI) of the
head (Figure 1A+C).
Physical examination
The patient's neurological status on admission was nor-
mal. There were no clues to phakomatosis in the patient's
or in the family history. Neither did the clinical findings
point in this direction. No further seizures occurred after
initiation and starting phenytoin therapy.
Imaging and laboratory study
Initial MRI demonstrated a contrast-enhancing lesion in
the left frontal lobe and a smaller lesion in the right fron-
tal lobe (Figure 1A+C). No other focal lesions were iden-
tified. Laboratory tests were normal except for elevations
of the following parameters: D-dimer level of 254, neu-
ron-specific enolase level of 13.1, and lambda and kappa
light chain levels of 1.63 and 4.64, respectively. The CSF
cell count and protein content were normal.
Patient treatment
Since the lesions had no mass effect, initially a stereotactic
biopsy was obtained from the left frontal lesion. Histolog-
ically, a semimalignant melanocytoma with the differen-
tial diagnosis of a MPNST was diagnosed. The lesion was
then removed microneurosurgically. Postoperatively, the
patient underwent whole-brain irradiation (30Gy). Due
to the advanced stage of the malignancy and to gain con-
trol over further intracerebral metastasis, which were not
visible on the MRI, no local radiotherapy such as radiosur-
gery was chosen. No postoperative or radiation-related
complications were observed.
Fluorodeoxyglycose positron emission tomography (FDG
PET) identified no body lesions except for an area of
increased accumulation lateral to the right jugular vein,
which corresponded to an enlarged lymph node, suggest-
ing a nodal metastasis on MRI. PET even failed to demon-
strate the right frontal lesion that was still present prior to
cerebral irradiation. Only whole-body MRI (T2WI) identi-
fied several structures of increased signal intensity in the
right thigh. One of the lesions was contiguous with the
sciatic nerve (Figure 2 and 3). The radiologic criteria were
indicative of a peripheral nerve tumor, suggesting that this
was the primary tumor. Spinal MRI demonstrated further
metastases at the level of S1 and S2 but no relationship to
spinal nerves (Figure 4).
Based on the patient's poor prognosis due to extensive
local tumor spread and the presence of distant cerebral
and vertebral metastases and a high risk of neurological
deficits associated with a resection of the thigh tumors, a
removal was considered unjustified. Stigmata of neurofi-
bromatosis were excluded, as were pulmonary and vis-
ceral metastases.
Postoperative follow-up
The first follow-up examination was performed after 3
months. MRI identified no tumor recurrence in the left
frontal lobe and no progression of the lesion on the right
(Figure 1B+D). The patient had no clinical or neurological
symptoms and suffered no seizures on continuous pheny-
toin medication (300 mg/day). At the last follow-up 11
months later, MRI showed unchanged cerebral findings
and no progression of the lumbar vertebral lesions. How-
ever, there was an increase in the size of the cervical lymph
node metastasis, and MRI for the first time demonstrated
metastases in the area of the right thigh. Nevertheless, the
patient continued to be free of neurologic deficits or epi-
leptic seizures and no further therapy was initiated.
Histology
Hematoxylin-eosin (H&E) staining demonstrated tumor
tissue with spindled epithelioid cells, some of which con-
tained melanin (Figure 5A+B). The cells were arranged in
nestlike clusters with an altogether heterogeneous appear-
ance. Immunohistochemically, strong expression of
vimentin (dilution 1:600; Zymed, Wien/Austria) and S-
100 (dilution 1:6000; DAKO, Glostrup/Denmark) was
demonstrated (Figure 5C+D). The pigmented cells were
positive for HMB45 (dilution 1:500; DAKO, Glostrup/
Denmark) and there was isolated expression of EMA
(dilution 1:100; DAKO, Glostrup/Denmark). The overall
expression of Ki67 antigen (dilution 1:200; DAKO, Glos-
trup/Denmark) was low, but some foci with an index of
30% were identified. There was no immunoreaction to
LU-5 (cytokeratin; dilution 1:500; Biomedicals, Augst/
Switzerland), NF (neurofilament; dilution 1:200; Zymed,
Wien/Austria), or SYN (synaptophysin; dilution 1:150;
BioGenex; San Ramon/U.S.A.). Furthermore electron
microscopy investigation showed a basal lamina, strongly
indicating peripheral nerve origin. The histological diag-
nosis of MPNST was based on the demonstration of spin-BMC Neurology 2007, 7:2 http://www.biomedcentral.com/1471-2377/7/2
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dled cells and their arrangement, the pattern of
immunoreactions as well as the electron microscopy
investigation. Due to the overall low expression of the
Ki67 antigen and the histological characterization, the
tumor was graded WHO°I, according to the WHO classi-
fication for soft-tissue tumors[5]. The histological diagno-
sis was verified by several reference pathologists.
Conclusion
The diagnosis of a MPNST is a clinical challenge for the
physician regarding treatment options and additional
diagnostic steps. In particular, if the tumor has spread into
the Central Nervous System. No uniform criteria have
been established for the treatment of MPNST outside the
central nervous system. However, it is widely agreed that
A, C Pre-Operative MRI: contrast-enhancing lesion in the left and right frontal lobe Figure 1
A, C Pre-Operative MRI: contrast-enhancing lesion in the left and right frontal lobe. B MRI follow-up after 6 month: no recur-
rence of the tumor after resection and irradiation (left frontal). D MRI follow-up after 6 month: no progression of the tumor 
after irradiation only (right frontal).BMC Neurology 2007, 7:2 http://www.biomedcentral.com/1471-2377/7/2
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the extent of surgical resection is an important prognostic
factor while no definitive data is available on the benefit
of postoperative radiotherapy[2]. Irradiation seems to
reduce local recurrence but does not affect the overall sur-
vival rate. Evidence for any relevant cytotoxic effect of
chemotherapy (doxorubicin, ifosfamide) is not availa-
ble[7]. Chemotherapy is performed only with palliative
intent.
In most published cases of MPNST metastasizing to the
cerebral parenchyma, the metastasis was removed micro-
surgically. The majority of reports are from Japan (Table
1). In some cases, surgical resection was followed by
whole-brain irradiation. Our case is of interest because the
patient had two cerebral metastases of which only one
was removed surgically. It is thus possible to compare the
outcome after combined surgery and radiotherapy with
the outcome after irradiation only. In our case, there has
been local tumor control of both metastases for 14
months so far. Therefore we conclude that whole-brain
irradiation without prior surgical removal or a radiosurgi-
cal approach in treating cerebral metastasis of a MPNST is
the best choice.
MPNST in general has an unfavorable prognosis with a 5-
year survival rate of only 64%. Survival is even much
shorter in patients with a brain metastasis and is not
affected by the therapeutic approach. A definitive
appraisal of the situation is difficult because only few
patients have been treated so far. One patient survived for
18 months without treatment [8] whereas another died a
few months after total resection of a brain metastasis[9].
In our case, resection and irradiation have so far sup-
pressed local cerebral recurrence for a total of 14 months
while there has been progression of the other distant
metastases. Given the rapid tumor progression in our
case, cautious therapy with little harm to the patient is
indicated.
Beside the clinical challenge of a new diagnose MPNST,
the pathologist has to deal with a great work up in the
beginning to provide the physician with a correct diagno-
sis. The histological diagnosis of MPNST requires careful
differentiation from a number of tumor entities with sim-
ilar histologic features. In general, MPNST cells have
either an epithelioid or spindled architecture with gradual
transitions between the two. The spindled type must be
carefully differentiated from other spindled-cell soft tissue
tumors, in particular fibrosarcoma. An immunoreaction
Whole-body MRI (T1WI+Gd) axial sacral slice, identified  structure of increased signal intensity in close relation to the  right sciatic nerve Figure 3
Whole-body MRI (T1WI+Gd) axial sacral slice, identified 
structure of increased signal intensity in close relation to the 
right sciatic nerve.
Whole-body MRI (T2WI) identified structure of increased  signal intensity in close relation to the sciatic nerve (arrow) Figure 2
Whole-body MRI (T2WI) identified structure of increased 
signal intensity in close relation to the sciatic nerve (arrow).BMC Neurology 2007, 7:2 http://www.biomedcentral.com/1471-2377/7/2
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to S-100 as in our case excludes a fibrosarcoma and under-
lines the close association of MPNST with the nerve
sheaths[9,10]. Another tumor to be considered in the dif-
ferential diagnosis in our patients was malignant
melanoma because some cells were found to contain mel-
anin on microscopic inspection. However, a malignant
melanoma could be excluded because there was no
immunoreaction to LU-5 (cytokeratin), which is only
expressed in some epitheloid variants of melanomas.
Whereas vimentin positivity as in this case, occurs also in
high malignant melanomas. Nevertheless, evidence of a
basal lamina by electron microscopy investigation
strongly indicates the tumor as a MPNST by nerve sheath
origin. In the case presented here, the tumor was further
characterized as a melanocytic MPNST because the mela-
nin-containing cells were found to be positive for HMB45.
Spinal sagittal MRI (T1WI+Gd) identified tumors in the sacral section of spinal column (S1 and S2) Figure 4
Spinal sagittal MRI (T1WI+Gd) identified tumors in the sacral section of spinal column (S1 and S2).BMC Neurology 2007, 7:2 http://www.biomedcentral.com/1471-2377/7/2
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A Hematoxylin-Eosin (H&E) staining, with polymorphic, spindled cells in nestlike clusters (10×) Figure 5
A Hematoxylin-Eosin (H&E) staining, with polymorphic, spindled cells in nestlike clusters (10×). B Melanin within epitheloid 
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Table 1: Cases of MPNST with brain metastasis
Case Author Age/Sex NF1) Site of primary tumor Localization of Brain metastasis Treatment of brain metastasis Survival time 2)
1 D'Agostino, 1963 [11] 22/f yes Cytomatic process Temporal Not given Not given
2 White, 1971 [12] 20/m yes Lumbar spinal nerve Medulla oblongata Not given Not given
3 Doi, 1983 [13] 23/m yes Chest Multiple Incomplete resection, irradiation 3 months
4 Hasegawa, 1984 [14] 51/m yes Thoracolumbar spinal nerve Sylvian fissure None (biopsy only) 3 1/2 months
5 Hirose, 1989 [15] 53/m no Paravertebral muscle Parietal Resection, irradiation, chemotherapy Not given
6 D'Angelo, 1991 [16] 68/f no Lower arm Parieto-occipital Resection 13 months
7 Fenzi, 1995 [8] 45/f no Brachial plexus Parietal None 18 months
8 Haisa, 1996 [17] 58/f no Maxillary sinus Dura mater Resection Days3)
9 Oishi, 2000 [18] 48/m no Abdomen Frontal Resection Not given
10 Tsuchiya, 2004 [19] 84/f no Medial angle of eye Not given Not given Not given
11 Matyja, 2004 [9] 33/m No Chest Multiple Resection Months4)
1) Type 1 neurofibromatosis
2) After diagnosis of a brain metastasis
3) Postoperative death due to hemoptysis
4) No. of months not specified